Abstract | UNLABELLED:
TNFalpha antagonists are effective in the treatment of chronic inflammatory joint disease. Despite a good overall safety profile, they can induce a number of adverse effects, including autoimmunity and infections. A link between TNFalpha antagonists and vasculitides has been suggested. METHODS: Between December 2004 and January 2005, a nationwide survey was conducted among 1200 hospital-based rheumatologists and internists in France, who were asked to report cases of vasculitis in patients taking TNFalpha antagonists. RESULTS: The survey identified 39 cases (32 women) of vasculitis during TNFalpha antagonist therapy. The joint disease was rheumatoid arthritis (RA) in 34 patients (including four without rheumatoid factor), juvenile idiopathic arthritis in two patients, ankylosing spondylitis in two patients, and psoriatic arthritis in one patient. Mean disease duration was 14.1+/-8.7 years. The TNFalpha antagonist was etanercept in 21 patients, infliximab in 15, adalimumab in 2, and another drug in 1; mean treatment duration was 9.6 months. The manifestations of vasculitis involved the skin (n=32); peripheral nervous system (n=9); kidney (n=7); central nervous system (n=3); pleura (n=2), pericardium (n=2); and the lung, gallbladder, and heart (n=1 each). Antinuclear factor ( ANF) was present in 22 patients, hypocomplementemia in 6, and antineutrophil cytoplasmic antibody in 5. Histology (30 biopsies from 27 patients) showed nonnecrotizing vasculitis in 12 patients, necrotizing vasculitis in 7, an inflammatory dermal infiltrate without vasculitis in 3, extravascular necrotic granulomas in 2, chilblain lupus in 1, and cicatricial fibro-inflammatory changes in 1. Renal biopsy in three patients showed extracapillary glomerulonephritis with IgA deposits (n=2) or active floccular necrosis against a background of glomerular sclerosis (n=1). TNFalpha antagonist therapy was stopped in 33 patients, among whom 18 recovered without further treatment and 14 required high-dose glucocorticoids and/or immunosuppressant therapy, which ensured symptom resolution within a few weeks. The remaining patient died with multiple organ failures. DISCUSSION:
|
Authors | Bernadette Saint Marcoux, Michel De Bandt, CRI (Club Rhumatismes et Inflammation) |
Journal | Joint bone spine
(Joint Bone Spine)
Vol. 73
Issue 6
Pg. 710-3
(Dec 2006)
ISSN: 1778-7254 [Electronic] France |
PMID | 17127088
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha
- Infliximab
- Adalimumab
- Etanercept
|
Topics |
- Adalimumab
- Adult
- Antibodies, Monoclonal
(adverse effects)
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
(adverse effects)
- Arthritis, Psoriatic
(drug therapy)
- Arthritis, Rheumatoid
(drug therapy)
- Biopsy
- Data Collection
- Etanercept
- Female
- France
- Humans
- Immunoglobulin G
(adverse effects)
- Infliximab
- Male
- Middle Aged
- Receptors, Tumor Necrosis Factor
- Spondylitis, Ankylosing
(drug therapy)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
- Vasculitis
(chemically induced, pathology)
|